Research programme: androgen receptor antagonists - Bristol-Myers SquibbAlternative Names: BMS 501949; BMS 647176; BMS-779333
Latest Information Update: 07 May 2010
At a glance
- Originator Bristol-Myers Squibb
- Class Aza compounds; Heterocyclic bicyclo compounds; Hydantoins; Small molecules
- Mechanism of Action Androgen receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Prostate cancer